Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Restructuring Costs (2019)

Seres Therapeutics' Restructuring Costs history spans 1 years, with the latest figure at $1.5 million for Q1 2019.

  • For Q1 2019, Restructuring Costs changed N/A year-over-year to $1.5 million; the TTM value through Dec 2019 reached $1.5 million, changed N/A, while the annual FY2019 figure was $1.5 million, N/A changed from the prior year.
  • Restructuring Costs for Q1 2019 was $1.5 million at Seres Therapeutics.
  • Across five years, Restructuring Costs topped out at $1.5 million in Q1 2019 and bottomed at $1.5 million in Q1 2019.